Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep;25(141):278-86.
doi: 10.1183/16000617.0090-2015.

Cough in idiopathic pulmonary fibrosis

Affiliations
Review

Cough in idiopathic pulmonary fibrosis

Mirjam J G van Manen et al. Eur Respir Rev. 2016 Sep.

Abstract

Many patients with idiopathic pulmonary fibrosis (IPF) complain of chronic refractory cough. Chronic cough is a distressing and disabling symptom with a major impact on quality of life. During recent years, progress has been made in gaining insight into the pathogenesis of cough in IPF, which is most probably "multifactorial" and influenced by mechanical, biochemical and neurosensory changes, with an important role for comorbidities as well. Clinical trials of cough treatment in IPF are emerging, and cough is increasingly included as a secondary end-point in trials assessing new compounds for IPF. It is important that such studies include adequate end-points to assess cough both objectively and subjectively. This article summarises the latest insights into chronic cough in IPF. It describes the different theories regarding the pathophysiology of cough, reviews the different methods to assess cough and deals with recent and future developments in the treatment of cough in IPF.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Disclosures can be found alongside the online version of this article at err.ersjournals.com

Figures

FIGURE 1
FIGURE 1
Pathophysiology of cough. TRPV1: transient receptor potential vanilloid 1; TRPA1: transient receptor potential ankyrin 1; RAR: rapidly adapting receptor; SAR: slowly adapting receptor. Reproduced from [17] with permission from the publisher.
FIGURE 2
FIGURE 2
Interactions between idiopathic pulmonary fibrosis (IPF), gastro-oesophageal reflux disease (GORD), obstructive sleep apnoea (OSA) and cough. 1: traction leading to a weaker lower oesophageal sphincter tonus [45]; 2: microaspiration inducing epithelial damage [38, 46]; 3: restriction inducing instability of the upper airway [39]; 4: intermitted hypoxaemia promoting profibrotic mechanisms [49]; 5: increased cough reflex sensitivity [–31]; 6: pressure causing stretch injury and activation of fibrotic mechanisms [31]; 7: microaspiration causing an inflammatory reaction blocking the airway [53]; 8: obstruction increasing trans-diaphragmatic pressure [51, 52]; 9: aspiration directly and acid reflux indirectly stimulate the cough reflex [6, 47]; 10: cough increasing trans-diaphragmatic pressure [47]; 11: less central inhibition and inflammation increasing cough reflex sensitivity [54].

References

    1. Raghu G, Collard HR, Egan JJ, et al. . An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824. - PMC - PubMed
    1. Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA). The Voice of the Patient: A series of reports from the U.S. Food and Drug Administration's (FDA's) Patient-Focused Drug Development Initiative. www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM44... Date last updated: March, 2015.
    1. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083–2092. - PubMed
    1. Richeldi L, du Bois RM, Raghu G, et al. . Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082. - PubMed
    1. Ryerson CJ, Abbritti M, Ley B, et al. . Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology 2011; 16: 969–975. - PubMed

Substances